Posted by Larry Hoover on May 23, 2006, at 19:10:26
In reply to Re: Trouble urinating on various meds? » Larry Hoover, posted by Phillipa on May 23, 2006, at 18:23:29
> Lar are you serious? Love Phillipa
I wouldn't joke about that. Duloxetine was first approved for stress urinary incontinence. It is known to so powerfully constrict the outlet valve on the bladder (in extreme cases) that a syringe was needed to evacuate it. Catheters couldn't pass.
I bet they don't hardly mention that effect in the "antidepressant" monograph. Like using Wellbutrin for smoking cessation, under Zyban.
It's all about the money, eh?
Curr Opin Investig Drugs. 2000 Sep;1(1):116-21.Duloxetine Eli Lilly & Co.
Pitsikas N.
Boehringer Ingelheim, Via Lorenzini 8, Milan 20139, Italy. nikpit@yahoo.it
Lilly is developing duloxetine, a 5-HT and norepinephrine uptake inhibitor as a potential treatment for depression and urinary incontinence. In Japan, it is being jointly developed with Shionogi [187401]. Phase III trials for depression and phase II trials for urinary incontinence are underway in Japan [296442,328887]. Lilly expects to file for depression in 2002 and phase III trials for urinary incontinence are planned to start enrollment by the end of 2000 [358429,370526,373870]. Duloxetine has a half-life of 10 to 15 h in humans, and parameters reach a steady-state after 3 days of daily administration. In a 6-week, open-label study duloxetine was safe and well tolerated in 79 clinically depressed patients. Clinical response occurred in 78% of patients, and remission occurred in 60%. Insomnia and nausea occurred with an incidence of 20% [300881]. Duloxetine may offer advantages over existing antidepressants, such as Lilly's fluoxetine, because of faster recovery and fewer side effects [190226]. In June 2000, Morgan Stanley Dean Witter predicted duloxetine would reach the market in 2002 with annual sales in this year of US $50 million, rising to $200 million in 2005 [373870]. In February 1999, Deutsche Bank predicted Lilly's sales at US $200 million in 2002 rising to $400 million in 2003 [316821]. In May 2000, Deutsche Bank had made further predictions, stating that filing for duloxetine is expected in the fourth quarter of 2001, and peak sales are expected to exceed US $500 million. Also in February 1999, Lehman Brothers predicted the first major launch date (US and ex-US) to be 2002, with the year of peak sales to be 2008 [319225]. In August 1999, this prediction changed, and the expected launch date became 2001, with an 80% probability of reaching the market and sales peaking at US $150 million in 2012 [349228].
poster:Larry Hoover
thread:647258
URL: http://www.dr-bob.org/babble/20060520/msgs/647486.html